D. Birkett

发表

Comparison of paracetamol metabolism in young adult and elderly males

J. Miners, R. Robson, R. Penhall, 2004, European Journal of Clinical Pharmacology.

Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia.

D. Birkett, P. Mcmanus, J. Marley, 1998, British journal of clinical pharmacology.

Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.

J. Miners, T. Andersson, U. Meyer, 1993, British journal of clinical pharmacology.

High-performance liquid chromatographic assay for human liver microsomal omeprazole metabolism.

J. Miners, T. Andersson, M. E. Veronese, 1993, Journal of chromatography.

Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450.

J. Miners, M. McManus, M. E. Veronese, 1990, Drug metabolism and disposition: the biological fate of chemicals.

Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid.

J. Miners, R. Robson, N. Grgurinovich, 1986, British journal of clinical pharmacology.

Cyclosporin-verapamil interaction.

R. Robson, D. Birkett, M. Fraenkel, 1988, British journal of clinical pharmacology.

Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.

R. Day, J. Miners, J. Hayes, 1988, British journal of clinical pharmacology.

Paraxanthine metabolism in humans: determination of metabolic partial clearances and effects of allopurinol and cimetidine.

J. Miners, A. Lelo, D. Birkett, 1989, The Journal of pharmacology and experimental therapeutics.

1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect.

R. Day, J. Miners, D. Birkett, 2003, British journal of clinical pharmacology.

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

G. Shenfield, J. Miners, J. Goldstein, 1996, Pharmacogenetics.

Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.

A. S. Gross, Suharjono, J. Miners, 2007, British journal of clinical pharmacology.

Variability of L-dopa absorption in man.

D J Birkett, D N Wade, P T Mearrick, 1974, Australian and New Zealand journal of medicine.

New Uses for Allopurinol

R. Day, P. Brooks, J. Miners, 1994, Drugs.

Lidocaine disposition—Sex differences and effects of cimetidine

J. Miners, L. Wing, S. Wanwimolruk, 1984, Clinical pharmacology and therapeutics.

A cost-effectiveness approach to drug subsidy and pricing in Australia.

A. Mitchell, D. Birkett, P. Mcmanus, 2001, Health affairs.

Structural requirements for drug binding to site II on human serum albumin.

P. Brooks, S. Wanwimolruk, D. Birkett, 1983, Molecular pharmacology.

The DNAzymes Rs6, Dz13, and DzF have potent biologic effects independent of catalytic activity.

A. Goodchild, L. Rivory, A. Lai, 2006, Oligonucleotides.

The formation of proximate carcinogens from three polycyclic aromatic compounds by human liver microsomes.

Sugiyanto, G. Holder, M. McManus, 1992, Xenobiotica; the fate of foreign compounds in biological systems.

Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.

J. Miners, L. Sansom, S. Pond, 1991, British journal of clinical pharmacology.

The Flinders experiment in medical education revisited

J. Alpers, D. Birkett, L. Geffen, 1991, The Medical journal of Australia.

Mechanisms of inhibition of tolbutamide metabolism: Phenylbutazone, oxyphenbutazone, sulfaphenazole

S. Pond, D. Wade, D. Birkett, 1977, Clinical pharmacology and therapeutics.

Specificity of the inhibitory effect of dextropropoxyphene on oxidative drug metabolism in man: effects on theophylline and tolbutamide disposition.

J. Miners, R. Robson, D. Birkett, 1987, British journal of clinical pharmacology.

The effect of sulphinpyrazone on oxidative drug metabolism in man: Inhibition of tolbutamide elimination

J. Miners, S. Wanwimolruk, A. Gallus, 2004, European Journal of Clinical Pharmacology.

Immunohistochemical localization of NADPH-cytochrome P450 reductase in human tissues.

I. Stupans, M. McManus, D. Birkett, 1989, Carcinogenesis.

Baculovirus-mediated expression of cytochrome P4502C8 and human NADPH-cytochrome P450 reductase: optimization of protein expression.

J. Miners, C. Bhasker, C. Ong, 1998, Xenobiotica; the fate of foreign compounds in biological systems.

Identification and quantitation in human liver of cytochromes P-450 analogous to rabbit cytochromes P-450 forms 4 and 6.

I. Stupans, R. Robson, M. McManus, 1988, Xenobiotica; the fate of foreign compounds in biological systems.

Characterisation of theophylline metabolism in human liver microsomes.

J. Miners, U. Meyer, R. Robson, 1987, British journal of clinical pharmacology.

Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain.

P. Lowenstein, M. Castro, D. Birkett, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination.

J. Miners, R. Robson, D. Birkett, 1984, British journal of clinical pharmacology.

Influence of sex and oral contraceptive steroids on paracetamol metabolism.

J. Miners, J. Attwood, D. Birkett, 1983, British journal of clinical pharmacology.

Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily.

J. Miners, P. Mackenzie, U. Meyer, 1993, The Biochemical journal.

Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques.

R. Tukey, J. Miners, F. Gonzalez, 1992, Pharmacogenetics.

Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser.

J. Miners, L. Wing, D. Birkett, 1985, Australian and New Zealand journal of medicine.

The effects of N-B transition of human serum albumin on the specific drug-binding sites.

S. Wanwimolruk, D. Birkett, 1982, Biochimica et biophysica acta.

Mechanism of action of paracetamol protective agents in mice in vivo.

J. Miners, R. Drew, D. Birkett, 1984, Biochemical pharmacology.

Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9.

J. Miners, D. Birkett, JO Miners, 1996, Methods in enzymology.

Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism

L. Bertilsson, M. Eichelbaum, R. Dahlqvist, 1984, Clinical pharmacology and therapeutics.

Metabolic disposition of the methylxanthines in man

J. Miners, J. Grygiel, D. Birkett, 1982 .

Cigarette smoking and theophyiiine clearance and metabolism

J. Grygiel, D. Birkett, 1981, Clinical pharmacology and therapeutics.

Effect of age on patterns of theophylline metabolism

J. Grygiel, D. Birkett, 1980, Clinical pharmacology and therapeutics.

Effects of allopurinol on theophylline metabolism and clearance

J. Grygiel, L. Wing, D. Birkett, 1979, Clinical pharmacology and therapeutics.

Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man.

J. Miners, R. Robson, A. Lelo, 1986, British journal of clinical pharmacology.

Effect of cimetidine on paracetamol activation in mice.

J. Miners, R. Drew, D. Birkett, 1984, Biochemical pharmacology.

Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology.

L. Gustafsson, I. Cascorbi, K. Brøsen, 2010, Basic & clinical pharmacology & toxicology.

Assays of omeprazole metabolism as a substrate probe for human CYP isoforms.

J. Miners, T. Andersson, D. Birkett, 1996, Methods in enzymology.

Effect of dexamethasone on cytochrome P-450 mediated metabolism of 2-acetylaminofluorene in cultured rat hepatocytes.

I. Stupans, M. McManus, A. Edwards, 1987, Biochemical pharmacology.

Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2.

R. Tukey, J. Miners, W. Tassaneeyakul, 1994, Pharmacogenetics.

Quantitative assessment of caffeine partial clearances in man.

J. Miners, R. Robson, A. Lelo, 1986, British journal of clinical pharmacology.

Profiles of antibacterial drug use in Australia and trends from 1987 to 1989: A report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee

A. Mitchell, D. Birkett, T. Grigson, 1991, The Medical journal of Australia.

Allelic and functional variability of cytochrome P4502C9.

J. Miners, C. Bhasker, S. Coulter, 1997, Pharmacogenetics.

Effects of tricyclic antidepressants on drug metabolism

G. Graham, S. Pond, D. Wade, 1975, Clinical pharmacology and therapeutics.

Relationships between plasma theophylline clearance, liver volume and body weight in children and adults

J. Grygiel, M. Ogborne, D. Birkett, 2004, European Journal of Clinical Pharmacology.

Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction.

J. Miners, J. Attwood, D. Birkett, 1983, British journal of clinical pharmacology.

Protein binding of non-steroidal antiinflammatory drugs in rheumatoid arthritis

P. Brooks, S. Wanwimolruk, D. Birkett, 1980 .

Protein binding of non-steroidal anti-inflammatory drugs in plasma and synovial fluid of arthritic patients.

P. Brooks, S. Wanwimolruk, D. Birkett, 1983, British journal of clinical pharmacology.

Protein Binding of some Non-steroidal Anti-inflammatory Drugs in Rheumatoid Arthritis

P. Brooks, S. Wanwimolruk, D. Birkett, 1982, Clinical pharmacokinetics.

Differential effects of cimetidine on theophylline metabolic pathways

J. Miners, J. Grygiel, R. Drew, 2004, European Journal of Clinical Pharmacology.

1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect.

R. Day, J. Miners, D. Birkett, 1991, British journal of clinical pharmacology.

Theophylline-rifampicin interaction: non-selective induction of theophylline metabolic pathways.

J. Miners, L. Wing, R. Robson, 1984, British journal of clinical pharmacology.

Secondary metabolism of theophylline biotransformation products in man--route of formation of 1-methyluric acid.

J. Miners, J. Attwood, D. Birkett, 1983, British journal of clinical pharmacology.

Action of urea on human alkaline phosphatases: with a description of some automated techniques for the study of enzyme kinetics.

S. Posen, R. Conyers, D. Birkett, 1967, Archives of biochemistry and biophysics.

The action of EDTA on human alkaline phosphatases.

S. Posen, R. Conyers, D. Birkett, 1967, Biochimica et biophysica acta.

Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines

J. Miners, R. Robson, A. Lelo, 1986, Clinical pharmacology and therapeutics.

Determinants of acetaminophen metabolism: Effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways

J. Miners, D. Birkett, J. Attwood, 1984, Clinical pharmacology and therapeutics.

Biochemical validation of self-reported caffeine consumption during caffeine fading

J. Miners, J. E. James, A. Lelo, 1988, Journal of Behavioral Medicine.

Spectroscopic techniques in the study of protein binding. A fluorescence technique for the evaluation of the albumin binding and displacement of warfarin and warfarin‐alcohol

D. Wade, D. Birkett, Gillian Sudlow, 1975, Clinical and experimental pharmacology & physiology.

Interaction of sulphinpyrazone with warfarin

J. Miners, S. Wanwimolruk, A. Gallus, 2004, European Journal of Clinical Pharmacology.

Clinical pharmacology of GP53,633—a new non-steroidal anti-inflammatory drug — in patients with rheumatoid arthritis

P. Brooks, J. Miners, S. Wanwimolruk, 1984, Agents and Actions.

Effects of fatty acids on two specific drug binding sites on human serum albumin.

G. Sudlow, S. Myers, D. Birkett, 1977, Molecular pharmacology.

Further characterization of specific drug binding sites on human serum albumin.

G. Sudlow, D J Birkett, D N Wade, 1976, Molecular pharmacology.

Probes for the conformational transitions of phosphorylase b. Effect of ligands studied by proton relaxation enhancement, fluorescence and chemical reactivities.

R. Dwek, G. Radda, A. Salmon, 1971, European journal of biochemistry.

Flavin-containing monooxygenase activity in human liver microsomes.

I. Stupans, M. McManus, D. Birkett, 1987, Drug metabolism and disposition: the biological fate of chemicals.

Dose, plasma concentration and response relationships of D-penicillamine in patients with rheumatoid arthritis.

P. Brooks, J. Miners, M. Smith, 1984, The Journal of rheumatology.

The characterization of two specific drug binding sites on human serum albumin.

G. Sudlow, D J Birkett, D N Wade, 1975, Molecular pharmacology.

Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.

R. Tukey, J. Miners, W. Tassaneeyakul, 1993, The Journal of pharmacology and experimental therapeutics.

Liquid-chromatographic determination of 5-fluorocytosine.

J. Miners, D. Birkett, T. Foenander, 1980, Clinical chemistry.

Liquid-chromatographic determination of 5-fluorocytosine.

J. Miners, D. Birkett, T. Foenander, 1980, Clinical chemistry.

Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations.

J. Miners, R. Robson, M. McManus, 1988, Biochemical pharmacology.

Pattern of non‐steroidal anti‐inflammatory drug use in Australia 1990–1994 A report from the Drug Utilization Sub‐Committee of the Pharmaceutical Benefits Advisory Committee

R. Day, J. Primrose, D. Henry, 1996, The Medical journal of Australia.

Characterization of chloroquine plasma protein binding in man.

L. Gustafsson, G. Alván, F. Sjöqvist, 1983, British journal of clinical pharmacology.

Continuous determination of enzyme activity during heat inactivation.

S. Posen, D. Birkett, F. C. Neale, 1966, Lancet.

RACEMATES OR ENANTIOMERS: REGULATORY APPROACHES

D. Birkett, D. J. Birkett, 1989, Clinical and experimental pharmacology & physiology.

The xenobiotic inhibitor profile of cytochrome P4502C8.

J. Miners, J O Miners, D J Birkett, 2000, British journal of clinical pharmacology.

Analysis of D-penicillamine in plasma by fluorescence derivatisation with N-[p-(2-benzoxazolyl)-phenyl] maleimide and high-performance liquid chromatography.

P. Brooks, J. Miners, M. Whitehouse, 1983, Journal of chromatography.

Localisation of aryl sulfotransferase expression in human tissues using hybridisation histochemistry and immunohistochemistry.

M. McManus, C. Bhasker, D. Birkett, 1998, Chemico-biological interactions.

The use of caffeine as a metabolic probe for human drug metabolizing enzymes.

J. Miners, D. Birkett, 1996, General pharmacology.

Caffeine renal clearance and urine caffeine concentrations during steady state dosing. Implications for monitoring caffeine intake during sports events.

J. Miners, D. Birkett, 1991, British journal of clinical pharmacology.

Serum Alkaline Phosphatase in Pregnancy: an Immunological Study

S. Posen, D. Birkett, F. C. Neale, 1966, British medical journal.

Intestinal alkaline phosphatase in human serum.

S. Posen, D. Birkett, F. C. Neale, 1967, American journal of clinical pathology.

Polymorphic hydroxylation of perhexiline in vitro.

J. Miners, A. Somogyi, L. Sorensen, 2003, British Journal of Clinical Pharmacology.

INTERACTION OF SOME DRUGS, METAL IONS, AND ALCOHOLS WITH RAT LIVER MICROSOMES AS STUDIED WITH A FLUORESCENT PROBE

D. Birkett, 1974 .

Characterization of paracetamol UDP-glucuronosyltransferase activity in human liver microsomes.

J. Miners, D. Birkett, K. Yoovathaworn, 1990, Biochemical pharmacology.

Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques.

J. Miners, F. Gonzalez, W. Tassaneeyakul, 1993, Biochemical pharmacology.

In vitro evidence for the involvement of at least two forms of human liver UDP-glucuronosyltransferase in morphine 3-glucuronidation.

J. Miners, D. Birkett, K. Lillywhite, 1988, Biochemical pharmacology.

Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes.

J. Miners, M. E. Jones, D. Birkett, 1988, Biochemical pharmacology.

Paracetamol metabolism in pregnancy.

J. Miners, R. Robson, D. Birkett, 1986, British journal of clinical pharmacology.

Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen.

R. Tukey, J. Miners, J O Miners, 1996, Biochemical pharmacology.

Interfering ribonucleic acids that suppress expression of multiple unrelated genes

M. Poidinger, A. Goodchild, G. Arndt, 2009, BMC Biotechnology.

Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m- and p-xylene.

R. Tukey, J. Miners, J. Edwards, 1996, The Journal of pharmacology and experimental therapeutics.

Pharmacokinetics made easy 10 Pharmacodynamics - the concentration-effect relationship

D. Birkett, 1995 .

Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects.

J. Miners, M. E. Veronese, D. Birkett, 1993, Pharmacogenetics.

Co-regulation of phenytoin and tolbutamide metabolism in humans.

J. Miners, L. Sansom, W. Tassaneeyakul, 1992, British journal of clinical pharmacology.

Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9.

J. Miners, P. Mackenzie, M. McManus, 1991, Biochemical and biophysical research communications.

Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers

J. Miners, M. E. Veronese, D. Birkett, 1990, Clinical pharmacology and therapeutics.

Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms.

R. Tukey, J. Miners, T. Andersson, 1994, Biochemical pharmacology.

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

J. Miners, J O Miners, D J Birkett, 1998, British journal of clinical pharmacology.

Structural and functional analysis of NADPH-cytochrome P-450 reductase from human liver: complete sequence of human enzyme and NADPH-binding sites.

T. Lee, J. Shively, M. Haniu, 1989, Biochemistry.

In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy

J. Murray, A. Jaramillo, G. Symonds, 2010, Retrovirology.

IMMUNOCHEMICAL AND CATALYTICAL CHARACTERIZATION OF THE HUMAN LIVER NADPH‐CYTOCHROME P450 REDUCTASE

A. Huggett, M. McManus, D. Birkett, 1989, Clinical and experimental pharmacology & physiology.

Temperature transitions of the microsomal hydroxylation system

S. Pond, D. Wade, D. Birkett, 1977 .

Simultaneous determination of pentoxifylline and its hydroxy metabolite in plasma by high-performance liquid chromatography.

J. Miners, D. Birkett, D. Chivers, 1981, Journal of chromatography.

Metabolism of benzo[a]pyrene. Effect of 3-methylcholanthrene pretreatment on metabolism by microsomes from lungs of genetically "responsive" and "nonresponsive" mice.

A. Y. Lu, D. Jerina, A. Conney, 1977, Archives of biochemistry and biophysics.

Spectroscopic techniques in the study of protein binding: the use of 1-anilino-8-naphthalenesulphonate as a fluorescent probe for the study of the binding of iophenoxic and iopanoic acids to human serum albumin.

G. Sudlow, D. Wade, D. Birkett, 1973, Molecular pharmacology.

Selective inhibitory effects of nifedipine and verapamil on oxidative metabolism: effects on theophylline.

J. Miners, R. Robson, D. Birkett, 1988, British journal of clinical pharmacology.

Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies.

J. Miners, I. Stupans, R. Robson, 1988, Biochemical pharmacology.

Pharmacokinetics made easy 9: Non-linear pharmacokinetics

D. Birkett, 1994 .

Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo.

J. Miners, W. Tassaneeyakul, D. Birkett, 2003, British journal of clinical pharmacology.

Quantitation of plasma warfarin levels by gas chromatography chemical ionization mass spectrometry.

A. Duffield, P. Duffield, D. Wade, 1979, Biomedical mass spectrometry.

Theophylline Metabolism by Human, Rabbit and Rat Liver Microsomes and by Purified Forms of Cytochrome P450

J. Miners, I. Stupans, M. McManus, 1988, The Journal of pharmacy and pharmacology.

The interactions between iophenoxic acid, iopanoic acid, bilirubin and human serum albumin as studied by fluorescence and Sephadex gel filtration.

J. Kapitulnik, D. Birkett, 1976, Clinica chimica acta; international journal of clinical chemistry.

Pharmacokinetics made easy: Therapeutic drug monitoring

D. J. Birkett, D. Birkett, 1997 .

In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.

J. Miners, T. Andersson, F. Gonzalez, 1994, British journal of clinical pharmacology.

Nonlinear Metabolic Disposition of Theophylline

J. Miners, R. Dahlqvist, D. Birkett, 1984, Therapeutic drug monitoring.

Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects.

R. Day, J. Miners, A. McLachlan, 2003, British journal of clinical pharmacology.

Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.

J. Miners, R. Walker, P. Coville, 2003, British journal of clinical pharmacology.

Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database.

A. Mant, S. Whicker, D. Birkett, 2010, Australian journal of public health.

Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9

S. Boye, J. Miners, R. Mckinnon, 2004, Xenobiotica; the fate of foreign compounds in biological systems.

Nonspecific binding of drugs to human liver microsomes.

J. Miners, J. McLure, D. Birkett, 2000, British journal of clinical pharmacology.

Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.

J. Miners, J. Goldstein, S. Coulter, 2000, Pharmacogenetics.

6-MERCAPTOPURINE-RELATED LEUCOPENIA AND IN VIVO XANTHINE OXIDASE ACTIVITY

P. Goadsby, R. Day, J. Miners, 1986, The Lancet.

Daring to dream : the future of Australian health care

S. Houston, S. Leeder, S. Duckett, 2001 .

Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.

R. Day, J. Miners, G. Graham, 1988, British journal of clinical pharmacology.

The effect of ranitidine on the disposition of lignocaine.

J. Miners, L. Wing, R. Robson, 1985, British journal of clinical pharmacology.

Warfarin and warfarin-alcohol levels in anticoagulated patients.

A. Duffield, P. Duffield, D. Wade, 1979, Australian and New Zealand journal of medicine.

Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia

D. Birkett, P. Mcmanus, J. Dudley, 2001, Pharmacoepidemiology and drug safety.

Generics - equal or not?

Donald J. Birkett, D. Birkett, 2003 .

A case for generic prescribing?

R. Robson, D. Birkett, 1983, The Medical journal of Australia.

Chapter 31. In Vitro Approaches for the Prediction of Human Drug Metabolism

J. Miners, M. E. Veronese, D. Birkett, 1994 .

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.

J. Miners, T. Andersson, M. E. Veronese, 1994, British journal of clinical pharmacology.

Metabolic drug interactions--a critical review.

S. Pond, D. Birkett, 1975, The Medical journal of Australia.

Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents.

J. Miners, W. Tassaneeyakul, D. Birkett, 1998, Xenobiotica; the fate of foreign compounds in biological systems.

Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.

J. Miners, M. E. Veronese, D. Birkett, 1995, The Journal of pharmacology and experimental therapeutics.

Perturbation of paracetamol urinary metabolic ratios by urine flow rate.

J. Miners, N. Osborne, A. Tonkin, 1992, British journal of clinical pharmacology.

A SIMPLE HPLC ASSAY FOR URINARY PARACETAMOL METABOLITES AND ITS USE TO CHARACTERIZE THE C3H MOUSE AS A MODEL FOR PARACETAMOL METABOLISM STUDIES

J. Miners, D. Birkett, J. F. Adams, 1984, Clinical and experimental pharmacology & physiology.

The reactivity of SH groups with a fluorogenic reagent

N. C. Price, G. Radda, D J. Birkett, 1970, FEBS letters.

Bioavailability and diurnal variation in absorption of sustained release theophylline in asthmatic children

J. Grygiel, K. Coulthard, N. Grgurinovich, 2004, European Journal of Clinical Pharmacology.

The effect of metoclopramide and atropine on the absorption of orally administered mexiletine.

P. Meffin, J. Grygiel, L. Wing, 1980, British journal of clinical pharmacology.

The misuse of urinary metabolite excretion data in drug metabolism studies.

J. Miners, D. Birkett, 1993, Pharmacogenetics.

Circadian variation in the absorption of three sustained release theophylline products in asthmatic children and the effect of food on absorption of Somophyllin-CRT.

K. Coulthard, N. Grgurinovich, D. Birkett, 1984, British journal of clinical practice. Supplement.

Effects of time of dose in relation to food on the bioavailability of Theo‐Dur Sprinkle at steady state in asthmatic children

D. Birkett, D. Lines, Garry M Kneebone, 1989, Clinical pharmacology and therapeutics.

The simultaneous determination of theophylline, theobromine and caffeine in plasma by high performance liquid chromatography.

J. Miners, L. Wing, D. Birkett, 1980, Clinical biochemistry.

Single Oral Dose Pharmacokinetics of Erythromycin and Roxithromycin and the Effects of Chronic Dosing

R. Robson, A. Tonkin, N. Grgurinovich, 1990, Therapeutic Drug Monitoring.

Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms.

J. Miners, T. Andersson, M. E. Veronese, 1994, British journal of clinical pharmacology.

Reversible metabolism of D-penicillamine in the rat.

J. Miners, D. Birkett, C. Bourke, 1984, Drug Metabolism And Disposition.

High-performance liquid chromatographic assay for 4-nitrophenol hydroxylation, a putative cytochrome P-4502E1 activity, in human liver microsomes.

J. Miners, W. Tassaneeyakul, M. E. Veronese, 1993, Journal of chromatography.

Theobromine metabolism in man.

J. Miners, J. Attwood, D. Birkett, 1982, Drug Metabolism And Disposition.

Mechanism of formation of 6-amino-5-(N-methylformylamino)-1-methyluracil and 3,7-dimethyluric acid from theobromine in the rat in vitro: involvement of cytochrome P-450 and a cellular thiol.

J. Miners, A. Lelo, D. Birkett, 1990, Xenobiotica; the fate of foreign compounds in biological systems.

Radiometric high-performance liquid chromatographic procedure for the determination of theobromine metabolites in microsomal incubations.

J. Miners, A. Lelo, D. Birkett, 1988, Journal of chromatography.

THEEFFECTOF METOCLOPRAMIDE AND ATROPINEON THE ABSORPTION OF ORALLYADMINISTEREDMEXILETINE

P. Meffin, J. Grygiel, L. Wing, 1980 .

Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it?

A. Mant, P. Mitchell, D. Birkett, 2001, British journal of clinical pharmacology.

The fatty acid content and drug binding characteristics of commercial albumin preparations.

G. Sudlow, S. Myers, D. Birkett, 1978, Clinica chimica acta; international journal of clinical chemistry.

Pharmacokinetics Made Easy

Donald J. Birkett, D. Birkett, 1999 .

Mja Guidelines for Assessing Qualitative Research Quality in Qualitative Research Criteria for Authors and Assessors in the Submission and Assessment of Qualitative Research Articles for the Medical Journal of Australia

G. Andrews, I. Baguley, D. Bennett, 2022 .

The Medical Journal of Australia

G. Andrews, I. Baguley, D. Bennett, 1965 .

Development of an Australian drug utilisation database: a report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee.

J. Primrose, D. Birkett, P. Mcmanus, 1993, PharmacoEconomics.

Metoclopramide, gastric emptying and L-dopa absorption.

D. Wade, D. Birkett, P. Mearrick, 1974, Australian and New Zealand journal of medicine.

A fluorescent probe for the dimer to tetramer conversion of glycogen phosphorylases a and b

G. Radda, A. Salmon, D. Birkett, 1970, FEBS Letters.

Glossary and tutorial of xenobiotic metabolism terms used during small molecule drug discovery and development (IUPAC Technical Report)

N. Bodor, S. Wrighton, H. Masumoto, 2021, Pure and Applied Chemistry.

A Quantitative Comparison of Anti-HIV Gene Therapy Delivered to Hematopoietic Stem Cells versus CD4+ T Cells

James A. Nichols, John M. Murray, Borislav Savkovic, 2014, PLoS Comput. Biol..

Application of the Fluorescent Probe 1-Anilinonaphthalene-8-Sulfonate to the Measurement of the Nonspecific Binding of Drugs to Human Liver Microsomes

A. Rowland, J. Miners, D. Elliot, 2011, Drug Metabolism and Disposition.

Nonspeciﬁc binding of drugs to human liver microsomes

J. Miners, J. McLure, D. Birkett, 2000 .

Immunohistochemical localization and quantitation of NADPH-cytochrome P-450 reductase in human liver.

I. Stupans, R. Robson, M. McManus, 1987, Molecular pharmacology.

The xenobiotic inhibitor proﬁle of cytochrome P4502C8

J. Miners, C. Bhasker, C. Ong, 2000 .

Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity.

S. Boye, J. Miners, D. Elliot, 2004, Biochemistry.

Direct and simultaneous high-performance liquid chromatographic assay for the determination of p-aminobenzoic acid and its conjugates in human urine.

J. Miners, K. Chan, D. Birkett, 1988, Journal of chromatography.

The kinetics of amitriptyline following single oral dose administration to man.

W. Garland, B. H. Min, D. Birkett, 1978, Research communications in chemical pathology and pharmacology.